Efficacy of Babaodan capsules in preventing catheter-associated urinary tract infection
Aim:To investigate the clinical effectiveness of Babaodan capsules in prevention of catheter-associated uri-nary tract infection(CAUTI).Methods:The patients with indwelling urinary catheters who were admitted to the Department of Urology of the First Affiliated Hospital of Zhengzhou University from June 2022 to February 2023 were selected and allo-cated into 3 groups according to the treatment;those who received standard antibiotic treatment after catheterization were control group(n=73),and those treated with Babaodan capsules,a combination of Babaodan capsules and antibiotics were named as trial group A(n=72)and trial group B(n=72),respectively.On the 3rd,5th and 7th day after catheterization,and 48 hours after catheter removal,urine routine and culture tests were conducted.The incidences of CAUTI,overactive bladder(OAB)and adverse reactions was compared among the 3 groups.Results:The incidence of total CAUTI in control group,trial group A and trial group B was 39.7%,36.1%and 20.8%,while the incidence of OAB was 30.1%,18.1%and11.1%,respectively.The incidences of CAUTI and OAB in trial group B were lower than those in the other2 groups(P<0.017).No adverse reactions occurred during the treatment in all3 groups.Conclusion:Babaodan capsules in combi-nation with antibiotics are effective in preventing CAUTI and have favourable safety.
万方数据
维普
